Entera Bio (ENTX)

• Market cap: $82.2M
• 1 day: 6.52%
• 5 days: 10.73%
• 1 month: 0.51%
• 3 months: -21.29%
• 6 months: 5.95%
• Year to date: -12.89%
• 1 year: -4.39%
• 5 years: 5.38%
• 10 years: -68.79%
• Sector: Healthcare
• Industry: Biotechnology

About: Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.

Employees: 20

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

150% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 2

58% more capital invested

Capital invested by funds: $10.1M [Q3] → $15.9M (+$5.82M) [Q4]

5.74% more ownership

Funds ownership: 14.65% [Q3] → 20.39% (+5.74%) [Q4]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q3] → 1 (+0) [Q4]

12% less funds holding

Funds holding: 17 [Q3] → 15 (-2) [Q4]

50% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 4

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $10 410% upside
• Avg. target: $10 410% upside
• High target: $10 410% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Raghuram Selvaraju 28% 1-year accuracy 94 / 334 met price target

410% upside $10

Buy Reiterated

18 Mar 2025